Caris Life Sciences, Inc. (CAI)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-28. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 18/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 12.89% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months
- Caris Life Sciences Unveils the Next Evolution of Liquid Biopsy with Enhanced Caris Assure
- Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look
- Caris Life Sciences Stock Jumped 10% Yesterday. Here’s Where Shares Could Go Further in 2026.
- Could Caris Life Sciences (CAI) Be 7% Undervalued After Its Lung Cancer Research Update?
- Caris Life Sciences (CAI) Will Present Seven Studies At A Global Lung Conference
- Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer
- Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Caris Life Sciences, Inc..
Full CAI Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.